Inspections, Compliance, Enforcement, and Criminal Investigations
Parmalat/Farmland Dairies 25-Jul-01
DEPARTMENT OF HEALTH & HUMAN SERVICES
Public Health Service
Food and Drug Administration
Watewiew Corporate Center
10 Waterview Blvd., 3rd Floor
Parsippany, NJ 07054
Telephone (973) 526-6010
Return Receipt Requested
Mr. Frank Polizzi
Vice President of Operations
520 Main Avenue
Wellington, New Jersey 07057
File No.: 01-NWJ-33
Dear Mr. Polizzi:
An inspection of your facility, located at 520 Main Avenue, Wellington, NJ, was conducted from November 16-21, 2000. During this inspection, our investigators collected a sample of your Westbrae Natural Rice Beverage product, lot 191101 FD-397930. Our review of your label and our analysis revealed that the product is considered misbranded according to Section 403(a)(l) and 403(r)(l)(A) of the Federal Food, Drug & Cosmetic Act (the Act) and Title 21, Code of Federal Regulations, Sections 101.9 and 101.54(e).
Our analysis found that the product contained significantly less than the labeled amounts of calcium and phosphorus. The Reference Daily Intake (RDI) of both calcium and phosphorus are 1,000 milligrams. Your label declares 25%DV (25% of the RDI) for calcium and 10% DV (10% of the RDI) for phosphorus. Our laboratory has reported original and check, and additional results of 16.1%, 9.64 %, and 21% of the declared amount of calcium and 31.6%, 23.5%, and 39.2% of the declared amount of phosphorus. These values correspond to %DV results of 4.02%, 2.41%, and 5.25% for calcium and 3.16%, 2.35%, and 3.92% for phosphorus.
In addition, the product label bears the nutrient content claim "Enriched... with.. .Calcium" but the product does not qualify for this claim, in part, because it contains less than 10% of the DV of calcium per eight fluid ounce serving.
The above violations are not meant to bean all-inclusive list of deficiencies on your label or at your-facility. Other label violations can subject the food to legal action. It is your responsibility to assure that all of your products are labeled in compliance with all applicable statutes enforced by FDA and manufactured in accordance with all applicable regulations.
Please notify this office within 15 working days of receipt of this letter outlining the specific steps you have taken to correct the violations noted above and to prevent their recurrence.
If corrective actions cannot be completed within 15 working days, state the reason for the delay and the time needed to complete the correction. Please submit your response to: U.S. Food & Drug Administration, 10 Waterview Boulevard, 3rd Floor, Parsippany, New Jersey 07054, Attn: Sarah A. Della Fave, Compliance Officer.
Douglas I. Ellsworth
New Jersey District